Table 1.

Patient characteristics

	Without PH	With PH	P value
	n= 123 (%)	n=20 (%)
Age (years)			0.019
Mean ± SD	66.8 ± 9.7	71.8 ± 6.7
Median (range)	68 (18–86)	73.5 (61–83)
Gender			0.048
Male	63 (51)	15 (75)
Female	60 (49)	5 (25)
Time (days) from MF diagnosis to ECHO			0.518
Mean ± SD	1547.5 + 1120.3	1836.7 ± 1578.1
Median (range)	1294 (21 – 6092)	1760 (251 – 7311)
MF type			0.470
PMF	72 (59)	12 (60)
Post-ET MF	21 (17)	5 (25)
Post-PV MF	30 (24)	3 (15)
JAK2 mutation present	67 (54)	11(55)	0.965
WHO grading myelofibrosis*			0.932
MF-1	16 (14)	2 (13)
MF-2	49 (43)	8 (50)
MF-3	50 (44)	6 (38)
DIPSS^			0.731
Low risk (0)	5 (4)	-
Intermediate-1 risk (1 to 2)	49 (40)	8 (40)
Intermediate-2 risk (3 to 4)	53 (43)	8 (40)
High risk (5 to 6)	15 (12)	4 (20)
Active therapy for MF	51 (41)	8 (40)	0.902
Co-morbid conditions
Hypertension	65 (53)	16 (80)	0.028
Hyperlipidemia	25 (20)	9 (45)	0.016
Coronary artery disease	10 (8)	6 (30)	0.004
Atrial fibrillation	5 (4)	1 (5)	≥0.999
Hypothyroidism	28 (23)	7 (35)	0.238
Diabetes Mellitus	11 (9)	1 (5)	≥0.999
COPD	5 (4)	1 (5)	≥0.999
Clinical
Dyspnea	13 (11)	7 (35)	0.003
ECOG performance status			0.845
0	48 (39)	6 (30)
1	65 (53)	13 (65)
2	8 (7)	1 (5)
≥3	2 (2)	-
Splenomegaly	76 (62)	16 (80)	0.137
Hepatomegaly	19 (15)	6 (30)	0.112
Active treatment	51 (41)	8 (40)	0.902

^*Data not available in *10 and

^{^}1 patient

PH, pulmonary hypertension; MF, myelofibrosis; ECHO, echocardiogram; PMF, primary myelofibrosis; Post-ET, myelofibrosis post-essential thrombocytopenia; Post-PV, myelofibrosis post-polycythemia vera; WHO, World Health Organization; DIPSS, dynamic international prognostic scoring system; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group